Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19

• Main Authors: Hayder M. Al-Kuraishy (Author), Ali I. Al-Gareeb (Author), Sarah M. Albogami (Author), Sabatier Jean-Marc (Author), Eman Hassan Nadwa (Author), Amin A. Hafiz (Author), Walaa A. Negm (Author), Marwa Kamal (Author), Mohammed Al-Jouboury (Author), Engy Elekhnawy (Author), Gaber El-Saber Batiha (Author), Michel De Waard (Author)
• Format: Book
• Published: MDPI AG, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Type 2 diabetes mellitus (T2DM) is a potential risk factor for the development of COVID-19 and is associated with higher severity and mortality rates. T2DM patients are commonly treated with metformin monotherapy or metformin plus sitagliptin. In the present case-control, single-center cohort study,...